Reference | </br>1:Extrapyramidal symptoms after exposure to calcium channel blocker-flunarizine or cinnarizine. Jhang KM, Huang JY, Nfor ON, Tung YC, Ku WY, Lee CT, Liaw YP.Eur J Clin Pharmacol. 2017 Apr 6. doi: 10.1007/s00228-017-2247-x. [Epub ahead of print] PMID: 28386684 </br>2:Bioadhesive floating microsponges of cinnarizine as novel gastroretentive delivery: Capmul GMO bioadhesive coating versus acconon MC 8-2 EP/NF with intrinsic bioadhesive property. Raghuvanshi S, Pathak K.Int J Pharm Investig. 2016 Oct-Dec;6(4):181-193. doi: 10.4103/2230-973X.195923. PMID: 28123987 Free PMC Article</br>3:Influence of drug load and physical form of cinnarizine in new SNEDDS dosing regimens: in vivo and in vitro evaluations. Siqueira SD, Müllertz A, Gräeser K, Kasten G, Mu H, Rades T.AAPS J. 2017 Mar;19(2):587-594. doi: 10.1208/s12248-016-0038-4. Epub 2017 Jan 9. PMID: 28070714 </br>4:Risk of parkinsonism induced by flunarizine or cinnarizine: a population-based study. Lin HL, Lin HC, Tseng YF, Chen SC, Hsu CY.Eur J Clin Pharmacol. 2017 Mar;73(3):365-371. doi: 10.1007/s00228-016-2181-3. Epub 2016 Dec 16. PMID: 27986997 </br>5:Full spectrum and selected spectrum based chemometric methods for the simultaneous determination of Cinnarizine and Dimenhydrinate in laboratory prepared mixtures and pharmaceutical dosage form. Tawakkol SM, El-Zeiny MB, Hemdan A.Spectrochim Acta A Mol Biomol Spectrosc. 2017 Feb 15;173:892-896. doi: 10.1016/j.saa.2016.10.055. Epub 2016 Nov 1. PMID: 27837737 </br>6:In vivo evaluation of supersaturation/precipitation/re-dissolution behavior of cinnarizine, a lipophilic weak base, in the gastrointestinal tract: the key process of oral absorption. Tanaka Y, Kawakami A, Nanimatsu A, Horio M, Matsuoka J, Wada T, Kasaoka S, Yoshikawa H.Eur J Pharm Sci. 2017 Jan 1;96:464-471. doi: 10.1016/j.ejps.2016.10.023. Epub 2016 Oct 20. PMID: 27773836 </br>7:Quality by design based fabrication of Iron oxide induced mucoadhesive microspheres for enhanced bioavalibility of cinnarizine. Singh I, Rana V.Curr Drug Deliv. 2016 Oct 18. [Epub ahead of print] PMID: 27758691 </br>8:Lipid-Based Formulations Can Enable the Model Poorly Water-Soluble Weakly Basic Drug Cinnarizine To Precipitate in an Amorphous-Salt Form During In Vitro Digestion. Khan J, Rades T, Boyd BJ.Mol Pharm. 2016 Nov 7;13(11):3783-3793. Epub 2016 Sep 27. PMID: 27631273 </br>9:An investigation into the crystallization tendency/kinetics of amorphous active pharmaceutical ingredients: A case study with dipyridamole and cinnarizine. Baghel S, Cathcart H, Redington W, O/’Reilly NJ.Eur J Pharm Biopharm. 2016 Jul;104:59-71. doi: 10.1016/j.ejpb.2016.04.017. Epub 2016 Apr 21. PMID: 27108783 </br>10:Enhanced bioavailability of cinnarizine nanosuspensions by particle size engineering: Optimization and physicochemical investigations. Mishra B, Sahoo J, Dixit PK.Mater Sci Eng C Mater Biol Appl. 2016 Jun;63:62-9. doi: 10.1016/j.msec.2016.02.046. Epub 2016 Feb 19. PMID: 27040196
|